South Korean-based Enzychem Lifesciences (KOSDAQ: 183490) just announced that the US Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to evaluate its lead therapeutic candidate EC-18, in a Phase 2 clinical trial in patients with Acute Respiratory Disease Syndrome (ARDS) due to COVID-19 pneumonia. A Phase 2 study for EC-18 in Preventing ARDS due to novel coronavirus pneumonia is currently ongoing in South Korea. Key opinion leader Dr. Cameron Robert Wolfe, from Duke University, signs on to lead the COVID-19 program in the United States. This study addresses a possible prevention of what becomes a very dangerous situation in COVID-19 patients.
A Dire Situation
The majority of individuals who get infected with SARS-CoV-2, the virus behind COVID-19, only have mild or moderate symptoms and can recover thanks to supportive care, suggests the World Health Organization. However, if someone develops a cough, fever, and difficulty breathing, this can lead to more severe problems, including a severe or critical condition called acute respiratory distress syndrome (ARDS). As Johns Hopkins Medicine lung disease expert Panagis Galiatsatos, MD,...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).